v3.25.1
Segment Information - Summary of Significant Expense Categories and Consolidated Net Loss Details (Details) - USD ($)
 3 Months Ended 12 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Dec. 31, 2024
Dec. 31, 2023
Research and development:        
GEM-AKI, GEM-CKD and GEM-PSI clinical study expenses $ 470,578 $ 333,225 $ 1,681,731 $ 209,702
Other expenses 23,613 [1] 89,015 [1] 172,369 [2] 282,948 [2]
Personnel expenses (including stock-based compensation) 364,639 295,342 1,227,195 765,330
General and administrative 1,236,157 1,184,556 4,426,113 4,510,762
Change in fair value of warrant liability (1,417) (68,427) (81,441) (8,328,937)
Other income (expense), net (42,485) [3] 847,722 [3] 7,144,868 [4] (207,473) [4]
Net loss $ (2,051,085) $ (2,681,433) $ (15,038,536) $ (120,254)
[1] Other research and development expenses primarily consist of facilities charges, third party consultant costs, costs related to other product candidates, and other unallocated costs.
[2] Other research and development expenses primarily consist of facilities charges, third party consultant costs, costs related to other product candidates, and other unallocated costs.
[3] Clinical trial related settlement expenses with A-IR Clinical Research Ltd., foreign currency transaction gains and losses and interest income from our cash balances in savings accounts.
[4] LifeSci Capital LLC judgment expense, reimbursement of costs, clinical trial related settlement expenses with A-IR Clinical Research Ltd., expense in connection with the deferred underwriting commissions, foreign currency transaction gains and losses and interest income from our cash balances in savings accounts.